A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma
Latest Information Update: 21 Nov 2025
At a glance
- Drugs Fluorine-18 FAPI 74 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Diagnostic use; Registrational
- Acronyms FAPI-PRO
- Sponsors SOFIE
Most Recent Events
- 18 Nov 2025 Planned initiation date changed from 15 Dec 2025 to 23 Dec 2025.
- 21 Oct 2025 New trial record
- 01 Oct 2025 According to a SOFIE Biosciences media release, company Alignment with FDA on study design to advance two Phase 3 Clinical trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F]FAPI-74.